Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MAGNET ALS lithium sub-study
NL-OMON54016Phase 3Recruiting
- Sponsor
- TRICALS
- Start
- Aug 2021
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of lithium carbonate in amyotrophic lateral sclerosis (ALS) and motor neuron disease (MND) (3 arms), sponsored by TRICALS. Primary endpoint: Overall survival. Started Aug 2021; status: recruiting.
02
Drugs
lithium carbonate
03
Conditions
amyotrophic lateral sclerosis (ALS)motor neuron disease (MND)
Beyond the preview
Go deeper on NL-OMON54016.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON54016.